{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021133","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.987237+00:00","generated_at":"2026-06-05T12:04:12.613595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alector reports Q4 net loss $41.4M; cash runway extended to 2026 after $75M equity offering","bullets":["Q4 net loss $41.4M ($0.49/sh) vs $52.4M ($0.63) YoY; FY net loss $130.4M ($1.56) vs $133.3M ($1.62).","Cash $548.9M at Dec 31; pro forma $620M after Jan 2024 equity offering, providing runway through 2026.","INVOKE-2 Phase 2 enrollment completed (381 pts); data due Q4 2024. Latozinemab granted FDA Breakthrough Therapy for FTD-GRN.","First patient dosed in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 for early AD in Feb 2024.","2024 guidance: collaboration revenue $60-70M, R&D $210-230M, G&A $60-70M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021133","json":"https://secwatch.observer/filing/0000950170-24-021133.json","markdown":"https://secwatch.observer/filing/0000950170-24-021133.md","text":"https://secwatch.observer/filing/0000950170-24-021133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/0000950170-24-021133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/alec-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:04:12.613595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94da0437cda00710cbd6da2ef711908a6fdf08f9","claim":"Alector, Inc. reported financial results for the quarter ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Alector, Inc. (the “Company”) announced its financial results for the quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017024021133/0000950170-24-021133-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}